2016 American Transplant Congress » Concurrent Session: Belatacept and Steroid Withdrawal in Kidney Transplantation

Date: Monday, June 13, 2016

Time: 4:30pm-6:00pm

Location: Ballroom A

Session Type: Concurrent Session

Meeting: 2016 American Transplant Congress

4:30pm-4:42pm: A Pathway to Belatacept Monotherapy: Alemtuzumab, Belatacept and Rapamycin for Kidney Transplantation.

A. Guasch,¹ H. Xu,² A. Mehta,¹ A. Ghali,¹ S. Mead,¹ H. Gebel,¹ R. Bray,¹ C. Larsen,¹ T. Pearson,¹ A. Kirk.²

4:42pm-4:54pm: The Optimal Time Point for Steroid Withdrawal After Kidney Transplantation Is One Year After Engraftment.

M. Haller,¹ M. Kammer,^1,2 A. Kainz,² G. Heinze,¹ R. Oberbauer.^1,2

4:54pm-5:06pm: Graft Survival of Steroid-Avoidance Protocols in Pediatric Kidney Transplantation[mdash]A Propensity Score Analysis.

E. Nehus,¹ Y. Wang,² B. Lu,³ C. Liu,² M. Macaluso,² M.-O. Kim.²

5:06pm-5:18pm: Early Steroid Withdrawal in African American Kidney Transplant Recipients: A Propensity Score Matching Analysis.

D. Taber, M. Gebregziabher, T. Srinivas, K. Chavin, P. Baliga, L. Egede.

5:18pm-5:30pm: Everolimus Plus Reduced-Exposure Cyclosporin versus Mycophenolic Acid Plus Cyclosporin: Seven-Year Follow-Up of Australia and New Zealand Kidney Transplant Recipients in the A2309 Study.

S. Chadban,¹ H. Pilmore,² G. Russ,³ J. Kanellis,⁴ S. Campbell,⁵ P. O'Connell,⁶ W. Lim,⁷ M. Lutherborrow,⁸ N. Kurstjens,⁸ R. Walker.⁹

5:30pm-5:42pm: Everolimus/Low Tacrolimus(TAC) Compared to MPA/RegularTAC for Renal Transplantation in the Elderly Recipient – Preliminary Analysis of the nEverOld Trial.

E. David-Neto,¹ F. Agena,¹ F. Ramos,¹ A. Triboni,¹ M. Altona,² V. Coelho,² N. Galante,¹ F. Lemos.¹

5:42pm-5:54pm: Comparison of Clinical Outcomes of Belatacept- and Tacrolimus-Based Immunosuppression in Renal Transplant Recipients.

X. Wen,¹ M. Casey,¹ A. Santos,¹ A. Hartzema,² K. Womer.¹

« View all sessions from the 2016 American Transplant Congress